Zydus Lifesciences wraps up enrollment for Phase II ALS trial of Usnoflast
Zydus Lifesciences, a renowned global pharmaceutical company, has achieved a significant milestone by completing the enrollment for the Phase II clinical trial of its novel oral NLRP3 inflammasome inhibitor, Usnoflast (ZYIL1), aimed at treating patients with Amyotrophic Lateral Sclerosis (ALS). This development marks a pivotal step in addressing the urgent need for effective treatments in […]